Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) Return on Invested Capital (2022 - 2025)

Prime Medicine filings provide 4 years of Return on Invested Capital readings, the most recent being 0.02% for Q1 2025.

  • On a quarterly basis, Return on Invested Capital changed 0.0% to 0.02% in Q1 2025 year-over-year; TTM through Mar 2025 was 0.02%, a 0.0% change, with the full-year FY2023 number at 0.01%, up 1.0% from a year prior.
  • Return on Invested Capital hit 0.02% in Q1 2025 for Prime Medicine, down from 0.01% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.01% in Q3 2022 to a low of 0.02% in Q4 2022.
  • Median Return on Invested Capital over the past 4 years was 0.01% (2023), compared with a mean of 0.01%.
  • The widest YoY moves for Return on Invested Capital: up 1bps in 2023, down -1bps in 2023.
  • Prime Medicine's Return on Invested Capital stood at 0.02% in 2022, then soared by 50bps to 0.01% in 2023, then increased by 19bps to 0.01% in 2024, then crashed by -56bps to 0.02% in 2025.
  • The last three reported values for Return on Invested Capital were 0.02% (Q1 2025), 0.01% (Q2 2024), and 0.01% (Q1 2024) per Business Quant data.